Landscape of genomic alterations in IDH wild-type glioblastoma identifies PI3K as a favorable prognostic factor

Yuanqing Yan*, Takeshi Takayasu, Gabriella Hines, Antonio Dono, Sigmund H. Hsu, Jay Jiguang Zhu, Roy F. Riascos-Castaneda, Arash Kamali, Meenakshi B. Bhattacharjee, Angel I. Blanco, Nitin Tandon, Dong H. Kim, Leomar Y. Ballester, Yoshua Esquenazi

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

18 Scopus citations


PURPOSE IDH wild-type (WT) glioblastoma (GBM) is an aggressive tumor with poor survival despite current therapies. The aim of this study was to characterize its genomic profile and determine whether a particular molecular signature is associated with improved survival outcomes. PATIENTS AND METHODS Tumor samples from 232 patients with IDH-WT GBM were sequenced, and the landscape of genomic alterations was fully delineated. Genomics data from The Cancer Genome Atlas (TCGA) cohort were analyzed for confirmation. Association of alterations with survival was evaluated in both univariable and multivariable approaches. RESULTS The genomic landscape of IDH-WT GBM revealed a high frequency of CDKN2A/B loss, TERT promoter mutations, PTEN loss, EGFR alteration, and TP53 mutations. Novel variants or gene mutations, such as ARID1B and MLL2, were identified. To better understand synergistic effects and facilitate decision making for precision medicine, we identified 11 pairs of gene alterations that tended to co-occur or were mutually exclusive, which were confirmed in the TCGA cohort. Survival analysis showed that genomic alterations in TP53 were associated with worse overall survival (OS). However, alterations in PI3K class I genes were associated with significantly better OS (univariable analysis: P = .002; multivariable analysis: hazard ratio [HR], 0.5785; P = .00162) and longer progression-free survival (univariable analysis: P = .0043; multivariable analysis: HR, 0.6228; P = .00913). CONCLUSION Genomic alterations in PI3K class I are a favorable prognostic factor in IDH-WT GBM. This new prognostic biomarker may facilitate risk stratification of patients, assist in clinical trial enrollment, and provide potential therapeutic targets.

Original languageEnglish (US)
Pages (from-to)575-584
Number of pages10
JournalJCO Precision Oncology
StatePublished - 2019

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Landscape of genomic alterations in IDH wild-type glioblastoma identifies PI3K as a favorable prognostic factor'. Together they form a unique fingerprint.

Cite this